|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TNRC6A |
Gene summary for TNRC6A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TNRC6A | Gene ID | 27327 |
| Gene name | trinucleotide repeat containing adaptor 6A | |
| Gene Alias | CAGH26 | |
| Cytomap | 16p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000288 | UniProtAcc | Q8NDV7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27327 | TNRC6A | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 4.58e-12 | 5.61e-01 | 0.1608 |
| 27327 | TNRC6A | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 6.22e-06 | 4.67e-01 | 0.1604 |
| 27327 | TNRC6A | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 4.49e-04 | 3.87e-01 | 0.1621 |
| 27327 | TNRC6A | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.91e-03 | 3.63e-01 | 0.1602 |
| 27327 | TNRC6A | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 7.31e-03 | 2.71e-01 | 0.1545 |
| 27327 | TNRC6A | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 7.26e-03 | 2.93e-01 | 0.1569 |
| 27327 | TNRC6A | P1_S1_AK | Human | Skin | AK | 3.30e-05 | 3.47e-01 | -0.3399 |
| 27327 | TNRC6A | P2_S3_AK | Human | Skin | AK | 2.92e-02 | 2.88e-01 | -0.3287 |
| 27327 | TNRC6A | P4_S8_cSCC | Human | Skin | cSCC | 3.64e-07 | 2.27e-01 | -0.3095 |
| 27327 | TNRC6A | P5_S10_cSCC | Human | Skin | cSCC | 6.99e-21 | 4.49e-01 | -0.299 |
| 27327 | TNRC6A | P1_cSCC | Human | Skin | cSCC | 2.41e-05 | 3.57e-01 | 0.0292 |
| 27327 | TNRC6A | P2_cSCC | Human | Skin | cSCC | 2.37e-10 | 3.61e-01 | -0.024 |
| 27327 | TNRC6A | P4_cSCC | Human | Skin | cSCC | 8.45e-04 | 2.15e-01 | -0.00290000000000005 |
| 27327 | TNRC6A | P10_cSCC | Human | Skin | cSCC | 5.44e-05 | 2.76e-01 | 0.1017 |
| 27327 | TNRC6A | male-WTA | Human | Thyroid | PTC | 6.04e-28 | 3.04e-01 | 0.1037 |
| 27327 | TNRC6A | PTC01 | Human | Thyroid | PTC | 3.45e-12 | 3.34e-01 | 0.1899 |
| 27327 | TNRC6A | PTC03 | Human | Thyroid | PTC | 2.72e-21 | 4.52e-01 | 0.1784 |
| 27327 | TNRC6A | PTC04 | Human | Thyroid | PTC | 1.55e-37 | 6.14e-01 | 0.1927 |
| 27327 | TNRC6A | PTC05 | Human | Thyroid | PTC | 4.06e-25 | 8.46e-01 | 0.2065 |
| 27327 | TNRC6A | PTC06 | Human | Thyroid | PTC | 4.40e-52 | 1.02e+00 | 0.2057 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
| GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
| GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
| GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
| GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
| GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
| GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
| GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
| GO:00092678 | Cervix | CC | cellular response to starvation | 39/2311 | 156/18723 | 1.04e-05 | 2.32e-04 | 39 |
| GO:00425948 | Cervix | CC | response to starvation | 46/2311 | 197/18723 | 1.24e-05 | 2.59e-04 | 46 |
| GO:00316698 | Cervix | CC | cellular response to nutrient levels | 49/2311 | 215/18723 | 1.32e-05 | 2.68e-04 | 49 |
| GO:00002896 | Cervix | CC | nuclear-transcribed mRNA poly(A) tail shortening | 13/2311 | 29/18723 | 1.48e-05 | 2.93e-04 | 13 |
| GO:00602119 | Cervix | CC | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 9/2311 | 15/18723 | 1.63e-05 | 3.17e-04 | 9 |
| GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
| GO:00009567 | Cervix | CC | nuclear-transcribed mRNA catabolic process | 30/2311 | 112/18723 | 2.60e-05 | 4.37e-04 | 30 |
| GO:00602139 | Cervix | CC | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 8/2311 | 13/18723 | 3.85e-05 | 6.05e-04 | 8 |
| GO:00002886 | Cervix | CC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 18/2311 | 56/18723 | 8.42e-05 | 1.13e-03 | 18 |
| GO:00610139 | Cervix | CC | regulation of mRNA catabolic process | 38/2311 | 166/18723 | 1.07e-04 | 1.36e-03 | 38 |
| GO:19033136 | Cervix | CC | positive regulation of mRNA metabolic process | 29/2311 | 118/18723 | 1.86e-04 | 2.18e-03 | 29 |
| GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TNRC6A | SNV | Missense_Mutation | novel | c.1531N>C | p.Glu511Gln | p.E511Q | Q8NDV7 | protein_coding | tolerated(0.13) | possibly_damaging(0.837) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TNRC6A | SNV | Missense_Mutation | novel | c.3425N>G | p.Glu1142Gly | p.E1142G | Q8NDV7 | protein_coding | tolerated(0.11) | benign(0.038) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| TNRC6A | SNV | Missense_Mutation | novel | c.847N>A | p.Leu283Ile | p.L283I | Q8NDV7 | protein_coding | tolerated(0.55) | benign(0.003) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| TNRC6A | SNV | Missense_Mutation | c.3223N>C | p.Asp1075His | p.D1075H | Q8NDV7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TNRC6A | SNV | Missense_Mutation | c.2810C>T | p.Ser937Leu | p.S937L | Q8NDV7 | protein_coding | deleterious(0.03) | benign(0.101) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TNRC6A | SNV | Missense_Mutation | c.5274N>T | p.Trp1758Cys | p.W1758C | Q8NDV7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TNRC6A | SNV | Missense_Mutation | c.1854N>A | p.Asn618Lys | p.N618K | Q8NDV7 | protein_coding | deleterious(0.01) | benign(0.036) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | PD | ||
| TNRC6A | SNV | Missense_Mutation | c.5350N>A | p.Val1784Ile | p.V1784I | Q8NDV7 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD | |
| TNRC6A | SNV | Missense_Mutation | c.5299N>T | p.Pro1767Ser | p.P1767S | Q8NDV7 | protein_coding | tolerated(0.15) | benign(0.158) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TNRC6A | SNV | Missense_Mutation | c.994G>A | p.Glu332Lys | p.E332K | Q8NDV7 | protein_coding | tolerated(0.14) | benign(0.018) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 27327 | TNRC6A | NA | ethanol | ALCOHOL | 32451486 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |